Adap­ti­m­mune rais­es $106M for pipeline work; Kalo­Bios chief says biotech is on track for Cha­gas drug fil­ing

→ Ma­trix Cap­i­tal Man­age­ment has scooped up $42 mil­lion worth of Adap­ti­m­mune stock $ADAP, pay­ing a slight pre­mi­um for the block of shares. “We are de­light­ed to wel­come Ma­trix to our share­hold­er base through a pur­chase of 7 mil­lion ADSs, which rais­es a fur­ther $42 mil­lion to add to the $62 mil­lion raised in our pub­lic of­fer­ing, which closed last week,” says CEO James No­ble.

→ Aus­tralia’s Novo­gen $NVGN is drop­ping a pre­clin­i­cal ther­a­py af­ter con­clud­ing that it didn’t have much of a fu­ture. It’s now cut­ting its head­count by an un­spec­i­fied num­ber and fo­cus­ing on its clin­i­cal ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER